Koronavirüs Hastalığı (COVID-19) Tedavisinde Kullanılan İlaçlar

SARS-CoV-2 virüsü Aralık 2019’da ortaya çıkmış ve başlangıçta Çin, Japonya ve Güney Kore olmak üzere tüm dünyada hızlıca yayılmıştır. Bilim insanları virüse spesifik antiviral bulmak için çabalamaktadır. Koronavirüs hastalığı 2019 (COVID-19) tedavisinde hidroksiklorokin, azitromisin, favipiravir, remdesivir, lopinavir/ritonavir gibi ilaçlar denenmektedir. Dünyada bu ilaçlar halen klinik çalışmalardan geçmektedir, bazı umut veren sonuçlara ulaşılmıştır. Bu makalede SARS-CoV-2’ye karşı güçlü etkinliği olan ilaçlar özetlenmektedir.

Anahtar Kelimeler:

covid-19, pnömoni, SARS-CoV-2, ilaç

Drugs Used in the Treatment of Coronavirus Disesase (COVID-19)

SARS-CoV-2 virus appeared in December 2019 and at the beginning spread in China, Japan, and South Korea, then all around the world. Scientists are trying to find specific antiviral to the virus. Hydroxychloroquine, azithromycin, favipiravir, remdesivir, lopinavir/ritonavir tried to be used in the treatment of coronavirus disease 2019 (COVID-19). These drugs are still in clinical trials in the world and there are some promising results. Drugs having efficacy against SARS-CoV-2 are summarised in this article.

Keywords:

COVID-19, pneumonia, SARS-CoV-2, drug,

PDF

___

Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-induced Pneumonia, The 5th ed. http://www.nhc.gov.cn/yzygj/s7653p/202002/d4b895337e19445f8d728fcaf1e3e13a/files/ab6bec7f93e64e7f998d802991203cd6.pdf (Erişim Tarihi: 18.02.2020). (in Chinese).
McCreary EK, Pogue JM. Coronavirus disease 2019 treatment: a review of early and emerging options. Open Forum Infect. Dis. 2020; 7(4): ofaa105. doi: 10.1093/ofid/ofaa105
Kalil AC. Treating COVID-19–Off-Label Drug Use,Compassionate Use, and Randomized Clinical Trials DuringPandemics. JAMA 2020. doi: 10.1001/jama.2020.4742
Uyeki TM, Bernstein HH, Bradley JS et al. Clinical practice guidelines by the infectious diseasessociety of America: 2018 update on diagnosis, treatment,chemoprophylaxis, and institutional outbreak management ofseasonal influenzaa. Clin. Infect. Dis. 2019; 68: e1.doi: 10.1093/cid/ciy866
Chan KS. Treatment of severe acute respiratory syndrome withlopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med. J. 2003; 9: 399-406.
Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-induced Pneumonia, The 6th ed. http:// www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326d d94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f9 22bf6b817.pdf (accessed February 23, 2020). (in Chinese).
Stockman LJ, Bellamy R, Garner P. SARS: Systematic review of treatment effects. PLoS Med. 2006; 3:e343.
Su B, Wang Y, Zhou R et al. Efficacy and tolerability of lopinavir/ritonavir- and efavirenz-based initial antiretroviral therapy in HIV-1- infected patients in a tertiary care hospital in Beijing, China. Front Pharmacol. 2019; 10:1472.
Chu CM, Cheng VCC, Hung IFN et al. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax. 2004; 59:252-256.
Savarino A, Di Trani L, Donatelli I et al. New insights into the antiviral effects of chloroquine. Lancet Infect Dis. 2006;6:67-69.
Wang M, Cao R, Zhang L et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020.
News: Abidol and darunavir can effectively inhibit coronavirus http://www.sd.chinanews. com/2/2020/0205/70145.html (accessed February 21, 2020). (in Chinese).
Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018;153:85-94.
Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad, Ser B, Phys Biol Sci. 2017;93:449-463.
News. http://www.szdsyy.com/News/0a6c1e58-e3d0-4cd1- 867a-d5524bc59cd6.html (accessed February 22, 2020). (in Chinese).
Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11:222.
Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020.
Mild/Moderate 2019-nCoV Remdesivir RCT. https:// clinicaltrials.gov/ct2/show/NCT04252664 (accessed February 22, 2020). (in Chinese).
Severe 2019-nCoV Remdesivir RCT. https://clinicaltrials. gov/ct2/show/NCT04257656 (accessed February 22, 2020). (in Chinese).
Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. 2020. 2020.2001.2031.929042.
Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB. Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion. J Virol. 2016;90:8924-8933.
Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proceedings of the Japan Academy Series B. 2017;93(7):449-463. doi:10.2183/pjab.93.027
Du YX, Chen XP. Favipiravir: pharmacokinetics and concern about clinical trials for 2019-nCoV infection. Clin. Pharmacol Ther. 2020. doi: 10.1002/cpt.1844
Gautret P, LagierJG, Parola P et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International J. Antimicrobial Agents 2020. doi:10.1016/j.ijantimicag.2020.105949.
Choy KT, Wong AYL, Kaewpreedee P et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020;178:104786. doi: 10.1016/j.antiviral.2020.104786.
Wang M, Cao R, Zhang L et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269- 71. doi: 10.1038/s41422-020-0282-0.
Holshue ML, DeBolt C, Lindquist S et al. First Case of 2019 Novel Coronavirus in the United States . N Engl J Med. 2020;382:929-936. doi:10.1056/NEJMoa2001191
Grein J, Ohmagari N, Shin D et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020. doi: 10.1056/NEJMoa2007016
Choy KT, Wong AYL, Kaewpreedee P et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020;178: 104786. doi: 10.1016/j.antiviral.2020.104786
Chu CM, Cheng VC, Hung IFN et al. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax. 2004;59:252-256. doi: 10.1136/thorax.2003.012658
Yao TT, Qian JD, Zhu Y, Wang Y, Wang GQ. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus–A possible reference for coronavirus disease‐19 treatment option. J. Med. Virol. 2020. doi: 10.1002/jmv.25729
Park SY, Lee JS, Son JS et al. Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers. J. Hospital Infection 2019;101(1):42-46. doi: 10.1016/j.jhin.2018.09.005
Young BE, Ong SWX, Kalimuddin S et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020. doi:10.1001/jama.2020.3204
Baden LR, Rubin EJ. Covid-19–The Search for Effective Therapy. N Engl J Med. 2020. doi: 10.1056/NEJMoa2001282
Wu J, Li W, Shi X et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients With novel coronavirus Disease (COVID-19). J. Int Med. 2020. doi: 10.1111/joim.13063
Rossignol JF. Nitazoxanide, a new drug candidate forthe treatment of Middle East respiratorysyndrome coronavirus. J. Infect. Public Health 2016;9:227-230. doi: 10.1016/j.jiph.2016.04.001
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020. doi: 10.1016/j. antiviral.2020.104787
Ketkar H, Yang L, Wormser GP, Wang P. Lack of efficacy of ivermectin for prevention of a lethal Zika virus infection in a murine system. Diag Microbiol Infect Dis. 2019;95(1):38-40. doi: 10.1016/j.diagmicrobio.2019.03.012